Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade

Systemic onset juvenile idiopathic arthritis (SoJIA) represents up to 20% of juvenile idiopathic arthritis. We recently reported that interleukin (IL) 1 is an important mediator of this disease and that IL-1 blockade induces clinical remission. However, lack of specificity of the initial systemic manifestations leads to delays in diagnosis and initiation of therapy. To develop a specific diagnostic test, we analyzed leukocyte gene expression profiles of 44 pediatric SoJIA patients, 94 pediatric patients with acute viral and bacterial infections, 38 pediatric patients with systemic lupus erythematosus (SLE), 6 patients with PAPA syndrome, and 39 healthy children. Statistical group comparison and class prediction identified genes differentially expressed in SoJIA patients compared with healthy children. These genes, however, were also changed in patients with acute infections and SLE. An analysis of significance across all diagnostic groups identified 88 SoJIA-specific genes, 12 of which accurately classified an independent set of SoJIA patients with systemic disease. Transcripts that changed significantly in patients undergoing IL-1 blockade were also identified. Thus, leukocyte transcriptional signatures can be used to distinguish SoJIA from other febrile illnesses and to assess response to therapy. Availability of early diagnostic markers may allow prompt initiation of therapy and prevention of disabilities.

[1]  J. Banchereau,et al.  Gene expression patterns in blood leukocytes discriminate patients with acute infections. , 2007, Blood.

[2]  R. Flavell,et al.  Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Gamero,et al.  IL-1 can act as number one. , 2006, Immunity.

[4]  Patricia Woo,et al.  Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome , 2006, Nature Clinical Practice Rheumatology.

[5]  Ryan M. O’Connell,et al.  MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. , 2006, Immunity.

[6]  G. Dubyak,et al.  Inhibitory Effects of Chloride on the Activation of Caspase-1, IL-1β Secretion, and Cytolysis by the P2X7 Receptor1 , 2005, The Journal of Immunology.

[7]  Virginia Pascual,et al.  Analysis of Significance Patterns Identifies Ubiquitous and Disease‐Specific Gene‐Expression Signatures in Patient Peripheral Blood Leukocytes , 2005, Annals of the New York Academy of Sciences.

[8]  P. Gage,et al.  A recently identified member of the glutathione transferase structural family modifies cardiac RyR2 substate activity, coupled gating and activation by Ca2+ and ATP. , 2005, The Biochemical journal.

[9]  J. Yagüe,et al.  Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). , 2005, Rheumatology.

[10]  P. Burbelo,et al.  The Role of SPECs, Small Cdc42-binding Proteins, in F-actin Accumulation at the Immunological Synapse* , 2005, Journal of Biological Chemistry.

[11]  C. Dinarello,et al.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease. , 2005, Arthritis and rheumatism.

[12]  P. Allen,et al.  Inflammatory arthritis requires Foxo3a to prevent Fas ligand–induced neutrophil apoptosis , 2005, Nature Medicine.

[13]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[14]  G. Firestein,et al.  Regulation of p38 MAPK by MAPK Kinases 3 and 6 in Fibroblast-Like Synoviocytes1 , 2005, The Journal of Immunology.

[15]  A. Solinger,et al.  Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. , 2005, Arthritis and rheumatism.

[16]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[17]  R. Priori,et al.  Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. , 2005, Rheumatology.

[18]  N. Wulffraat,et al.  Anakinra for flares of pyogenic arthritis in PAPA syndrome. , 2005, Rheumatology.

[19]  P. Meltzer,et al.  Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. , 2005, Blood.

[20]  J. Canas da Silva,et al.  Refractory adult onset Still's disease successfully treated with anakinra. , 2005, Annals of the rheumatic diseases.

[21]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Firestein,et al.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.

[23]  J. Verbsky,et al.  Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. , 2004, The Journal of rheumatology.

[24]  A Ravelli,et al.  Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. , 2004, Clinical and experimental rheumatology.

[25]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[26]  P. Hawkins,et al.  Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. , 2004, Arthritis and rheumatism.

[27]  D. Kastner,et al.  Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Martini,et al.  Early predictors of outcome in juvenile idiopathic arthritis. , 2003, Clinical and experimental rheumatology.

[29]  A. Prieur,et al.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. , 2003, Arthritis and rheumatism.

[30]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[31]  Ash A. Alizadeh,et al.  Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. McCurdy,et al.  Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. , 2003, The Journal of rheumatology.

[33]  E. Remmers,et al.  De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. , 2002, Arthritis and rheumatism.

[34]  M. Lovett,et al.  Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. , 2002, Human molecular genetics.

[35]  P. Woo,et al.  Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. , 2001, Clinical and experimental rheumatology.

[36]  R. Schneider,et al.  Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. , 2000, Arthritis and rheumatism.

[37]  C. Doré,et al.  Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. , 2000, Arthritis and rheumatism.

[38]  R. Cimaz,et al.  Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. , 2000, The Journal of rheumatology.

[39]  Wallace Ca,et al.  Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. , 1991, Rheumatic diseases clinics of North America.

[40]  C. Wallace,et al.  Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. , 1991, Rheumatic diseases clinics of North America.

[41]  Audrey M. Nelson,et al.  Textbook of Pediatric Rheumatology , 1990 .

[42]  R. Steinman,et al.  Interleukin 1 production during accessory cell-dependent mitogenesis of T lymphocytes , 1989, The Journal of experimental medicine.

[43]  J. Fries,et al.  A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[44]  C. Griscelli,et al.  [Prognosis of the systemic forms of juvenile chronic arthritis. Apropos of 100 cases]. , 1984, Archives francaises de pediatrie.